Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma

Experimental Oncology

Volumn 26, Issue 2, 2004, Pages 149-152

  Akbulut, Hakan ^a   Icli, Fikri ^a   Yalcin, Bulent ^a   Demirkazik, Ahmet ^a   Onur, Handan ^a   Buyukcelik, Abdullah ^a   Utkan, Gungor ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Advanced disease; Cisplatin; Colorectal carcinoma; Dacarbazine; Irinotecan

Indexed keywords

CISPLATIN; DACARBAZINE; FLUOROURACIL; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NAUSEA; SURVIVAL RATE; TREATMENT FAILURE; VOMITING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; NEUTROPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CAMPTOTHECIN; CISPLATIN; COLORECTAL NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3242742219     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cohen AM, Minsky BD, Schilsky RL. In: Cancer of the colon. De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, Fifth ed. Philadelphia: J.B.Lippincott Co., 1997; 1144-96.
2. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
3. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multi-center randomised trial. Lancet 2000; 355: 1041-7.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 905-4.
6. Icli F, Arican A, Cay F, Akbulut H, Dincol D, Karaoguz H, Demirkazik A. Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil. Oncology 1999; 56: 297-300.
7. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
8. Punt CJ. New drugs in the treatment of colorectal carcinoma. Cancer 1998; 83: 679-89.
9. The Advanced Colorectal Cancer Meta-Analysis Project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
10. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
11. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999; 35: 371-9.
12. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M. Two consecutive phase II studies of oxatiplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
13. Comella P, De Vita F, De Lucia L, Casaretti R, Avallone A, Orditura M, Rivellini F, Palmeri S, Catalano G, Comella G. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Ann Oncol 2000: 11: 461-8.
14. Chau I, Webb A, Norman A, Massey A, Hill M, Cunningham D. A phase II study of protracted venous infusion (PVI) 5-fluorouracil and oxaliplatin in patients with advanced or relapsed, 5-FU pretreated colorectal cancer. Proc ASCO 2001; 20: 140a (Abstract No:557).
15. Patel J, Kemeny N, Gonen M, DiLauro C, Stockman J. A study of continuous infusion (CI) of fluorouracil (FU) and oxaliplatin (OXA) for previously treated colorectal cancer patients. Proc ASCO 2001; 20: 143a (Abstract No:568).
16. Levi F, Zidani R, Coudert B, Giacchetti S, Brezault-Bonnet C, Manoux D, Dessard-Diana B, Maoudj E, Franco D, Adam R. Chronomodulated irinotecan (I)-fluorouracil (F)- leucovorin (L) - oxaliplatin (O) (Chrono IFLO) as salvage therapy in patients with heavily pre-treated metastatic colorectal cancer (MCC). Proc ASCO 2001; 20: 139a (Abstract No:552).
17. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A. Cemximab Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO 2001; 20: 3a(Abstract No:7).
18. Scheele J, Stang R, Altendorf-Hoffmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
19. Fong Y, Cohen AM, Fortner JG, Enker WE, Turn-bull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-46.